Diffuse panbronchiolitis after humanized anti-CCR4 monoclonal antibody therapy for relapsed adult T-cell leukemia/lymphoma.

Abstract

We present the case of a 62-year-old Japanese woman with relapsed adult T-cell leukemia/lymphoma (ATLL) who was treated with humanized anti-CCR4 monoclonal antibody (KW-0761). Although this antibody was highly effective against refractory ATLL, 6 months after the final KW-0761 infusion, the patient complained of hypoxia due to diffuse panbronchiolitis. Physicians should remain vigilant to the possibility of such previously unreported late-onset adverse effects associated with KW-0761 therapy.

• Authors: Koji Kato, Toshihiro Miyamoto, Akihiko Numata, Takashi Nakaike, Hideyo Oka, Ayano Yurino, Takuro Kuriyama, Yasuo Mori, Satoshi Yamasaki, Tsuyoshi Muta, Katsuto Takenaka, Hiromi Iwasaki, Takanori Teshima, Koichi Akashi
• Journal: International journal of hematology (Int J Hematol) Vol. 97 Issue 3 Pg. 430-2 (Mar 2013) ISSN: 1865-3774 [Electronic] Japan
• PMID: 23397210 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal, Humanized
• CCR4 protein, human
• Receptors, CCR4
• mogamulizumab

Topics

• Antibodies, Monoclonal, Humanized (administration & dosage, adverse effects)
• Bronchiolitis (chemically induced)
• Female
• Haemophilus Infections (chemically induced)
• Humans
• Hypoxia
• Leukemia-Lymphoma, Adult T-Cell (drug therapy, pathology)
• Middle Aged
• Receptors, CCR4
• Time Factors